Fulcrum Therapeutics to Present at the Stifel 2019 Healthcare Conference

CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that members of the management team will provide a business overview and update at the Stifel 2019 Healthcare Conference at 8:00 a.m. ET on Wednesday, November 20, 2019 in New York, NY.

A live webcast of the presentation will be available through the investor relations section of the Company's website at https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.

About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. Please visit www.fulcrumtx.com.

Investor Contact:Christina Tartaglia Stern Investor Relations, Inc. [email protected]212-362-1200

Media Contact: Lynn GranitoBerry & Company Public Relations[email protected]212-253-8881

You May Also Be Interested In

• NVIDIA Launches Open Agent Safety Platform to Secure Agents From Testing to Deployment
• HSBC Adopts Nasdaq Calypso’s Enhanced Exchange-Traded Derivatives Platform
• Lift Therapeutics Appoints Eva Ehrnrooth as Executive Head of Clinical Development and Adds Chau Khuong to Board of Directors